Skip to content

Study · Not a test of the peptide alone · 2005

3 results

[Antiviral therapy of chronic hepatitis B patients resistant to lamivudine].

Cui SN, Wang MM

Zhonghua shi yan he lin chuang bing du xue za zhi = Zhonghua shiyan he linchuang bingduxue zazhi = Chinese journal of experimental and clinical virology1 Dec 2005

PMID16416004 (opens in a new tab)DOI10.3760/cma.j.issn.1003-9279.2005.04.021 (opens in a new tab)PepBankPUB-16416004
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone3

In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Thymosin alpha-1.

  1. 01HumanNot a test of Thymosin alpha-1 aloneRandomized controlled trialEfficacy outcome

    In patients with hepatitis B resistant to lamivudine, hepatic function normalized more often with interferon alone or with interferon plus thymosin-alpha1 than in control.

    In plain wordsIn patients with hepatitis B resistant to lamivudine, liver function normalized more often with interferon, with or without thymosin alpha‑1, than in control.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseNormalization rate of hepatic function
    Study

    n = 66

    Comparator
    Control group (no antiviral drug after lamivudine withdrawal)
    Outcome group
    Liver fat and liver function · Liver

    Source sentences

    Summary
    Normalization rate of hepatic function, HBV DNA seroconversion rate and HBeAg/HBeAb seroconversion rate in two treatment groups were significantly higher than those in control group.
    1 context sentence
    Summary · context
    Sixty six patients with CHB resistant to lamivudine were enrolled and randomized into treatment group A, treatment group B and control group.

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  2. 02HumanNot a test of Thymosin alpha-1 aloneRandomized controlled trialEfficacy outcome

    In patients with hepatitis B resistant to lamivudine, HBV DNA seroconversion was higher with interferon alone or with interferon plus thymosin-alpha1 than in control.

    In plain wordsIn patients with hepatitis B resistant to lamivudine, virus DNA loss was more common with interferon, with or without thymosin alpha‑1, than in control.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseHBV DNA seroconversion rate
    Study

    n = 66

    Comparator
    Control group (no antiviral drug after lamivudine withdrawal)
    Outcome group
    Antiviral activity · Liver

    Source sentences

    Summary
    Normalization rate of hepatic function, HBV DNA seroconversion rate and HBeAg/HBeAb seroconversion rate in two treatment groups were significantly higher than those in control group.
    1 context sentence
    Summary · context
    Sixty six patients with CHB resistant to lamivudine were enrolled and randomized into treatment group A, treatment group B and control group.

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  3. 03HumanNot a test of Thymosin alpha-1 aloneRandomized controlled trialEfficacy outcome

    In patients with hepatitis B resistant to lamivudine, HBeAg/HBeAb seroconversion was higher with interferon alone or with interferon plus thymosin-alpha1 than in control.

    In plain wordsIn patients with hepatitis B resistant to lamivudine, HBeAg/HBeAb seroconversion was more common with interferon, with or without thymosin alpha‑1, than in control.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseHBeAg/HBeAb seroconversion rate
    Study

    n = 66

    Comparator
    Control group (no antiviral drug after lamivudine withdrawal)
    Outcome group
    Antiviral activity · Liver

    Source sentences

    Summary
    Normalization rate of hepatic function, HBV DNA seroconversion rate and HBeAg/HBeAb seroconversion rate in two treatment groups were significantly higher than those in control group.
    1 context sentence
    Summary · context
    Sixty six patients with CHB resistant to lamivudine were enrolled and randomized into treatment group A, treatment group B and control group.

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    12 Oct 2026, 17:28 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:02 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.